



COLORADO

Department of Health Care
Policy & Financing

Drug Utilization Review Board MEETING AGENDA

February 8, 2022

Open Session 1:00 pm to 5:00 pm

Zoom Link will be posted prior to the meeting at

<https://www.colorado.gov/pacific/hcpf/drug-utilization-review-board>

Health First Colorado, Colorado's Medicaid program

DUR Board Members	CO-DUR Team
Liza Wilson Claus, PharmD (Chair) Alison Shmerling, MD, MPH (Vice Chair) Miroslav Anguelov, PharmD Todd Brubaker, DO Brian Jackson, MD, MA Shilpa Klocke, PharmD Lyle Laird, PharmD Patricia Lanius, BSPHarm, MHA Scott VanEyck, MD	Jeffrey Taylor, PharmD (HCPF) Julia Rawlings, PharmD (CO DUR) Robert L Page II, PharmD, MSPH (CO DUR) Gina Moore, PharmD, MBA (CO DUR) Heather Anderson, PhD (CO DUR) Garth Wright, MPH (CO DUR) Vanessa Patterson, MPH (CO DUR)

A

1. Call to Order
2. Roll Call and Introductions
3. Virtual Meeting Information and General Announcements
4. Board Chair and Vice Chair Elections
5. Colorado Department of Health Care Policy and Financing Updates
6. Final Approval of Minutes from the November 9, 2021 Meeting
7. Reading of Rules for Public Testimony and Disclosure of Conflicts of Interest

Presentations:

- Agenda items must be approved in advance, including requests to present information. Please contact DUR Pharmacist, Jeffrey Taylor, at jeffrey.taylor@state.co.us
- Anyone wishing to provide testimony must contact the DUR Pharmacist at least 24 hours prior to the start of the meeting.

8. Clinical Updates and General Orders

- FDA New Product & Safety Updates
- Quarterly Module Summaries
- Retrospective DUR Reports
- Quarterly Drug Utilization Reports

Our mission is to improve health care equity, access and outcomes for the people we serve while saving Coloradans money on health care and driving value for Colorado.

<https://hcpf.colorado.gov>





COLORADO

Department of Health Care Policy & Financing

9. New Business (open for public testimony and Board review)

Proposed Criteria for PDL Drug Classes Scheduled for Review

- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) - Oral & Non-Oral
- Beta-Blockers & Combinations
- Anticonvulsants, Oral
- Newer Generation Antidepressants
- Anti-Parkinson's Agents
- Benzodiazepines (Non-Sedative Hypnotic)
- Atypical Antipsychotics - Oral & Topical
- Calcitonin Gene-Related Peptide Inhibitors (CGRPIs)
- Triptans, Ditans, and Other Migraine Treatments - Oral & Non-Oral
- Stimulants and Related Agents
- Growth Hormones
- Bile Salts
- Multiple Sclerosis
- Ophthalmics, Anti-Inflammatories
- **Mass review drug classes***
 - Non-Opioid Analgesia Agents - Oral & Topical
 - Opioids - Short-Acting, Fentanyl Preparations & Long-Acting
 - Alpha-Blockers & Calcium Channel Blockers
 - Lipotropics - Bile Acid Sequestrants, Fibrates, Other
 - Statins & Combinations
 - Monoamine Oxidase Inhibitors (MAOIs)
 - Tricyclic Antidepressants
 - Anxiolytics, Non-Benzodiazepine
 - Lithium Agents
 - Neurocognitive Disorder Agents
 - Sedative Hypnotics - Non-Benzodiazepine & Benzodiazepine
 - Skeletal Muscle Relaxants
 - Hemorrhoidal, Anorectal, and Related Topical Anesthetic Agents
 - Ophthalmics, Allergy
 - Ophthalmics, Immunomodulators
 - Ophthalmics, Glaucoma

* Proposed criteria for drug classes designated for mass review will not be read aloud at the time of DUR Board review, as there are no proposed changes to criteria currently implemented for these designated classes. The DUR Board may determine if designated mass review drug classes will undergo full review based on board vote.

Our mission is to improve health care equity, access and outcomes for the people we serve while saving Coloradans money on health care and driving value for Colorado.

<https://hcpf.colorado.gov>



**COLORADO****Department of Health Care
Policy & Financing**

10. Proposed Prior Authorization Criteria for Other Selected Products

- Xolair (omalizumab)
- Livtency (maribavir)
- Nexviazyme (avalglucosidase alpha)
- Voxzogo (vosoritide)
- Saphnelo (anifrolumab)
- Tyrvaya (varenicline)

11. Adjournment

Next meeting date

May 10, 2022

1:00 pm to 5:00 pm

Reasonable accommodations will be provided upon request. Auxiliary aids and services for individuals with disabilities and language services for individuals whose first language is not English may be provided upon request. Please notify the 504/ADA Coordinator or send an email to hcpf504ada@state.co.us at least one week prior to the meeting to make arrangements.

Our mission is to improve health care equity, access and outcomes for the people we serve
while saving Coloradans money on health care and driving value for Colorado.

<https://hcpf.colorado.gov>

